Sino-American immunotherapy-focused biotech LTZ Therapeutics and UK pharma major GSK have entered into a strategic research ...

Just a few weeks after the company announced licensing agreements with Empirico and Syndivia, GSK announced a strategic ...

GSK & LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology: London, UK Thursday, November 20, 2025, 09:00 Hrs [IST] GSK plc and LTZ Therapeutics ...

Moderna has announced a $140 million investment to enhance its Massachusetts manufacturing capacity, a move that supports ...

GSK teams with LTZ Therapeutics to co-develop next-gen myeloid-cell engager immunotherapies in oncology leveraging LTZ’s ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

I’ve noticed the smiles and a lot of 180 turns when people realize what they’re seeing. The whole reason I did it was to make ...

GSK (GSK) and LTZ Therapeutics announced a strategic research collaboration to advance the development of novel myeloid cell engagers, MCEs, to ...

Agios Pharmaceuticals Inc. reported top-line data from its 52-week Rise Up trial testing oral pyruvate kinase activator mitapivat in sickle cell disease (SCD), which hit statistical significance on ...

Publicize your non-profit’s community events, fundraisers and club meetings for free in The Stroller. Send information at ...

Immunotherapy-focused biotech company LTZ Therapetics Inc. and GSK plc are partnering to develop up to four potential first-in-class myeloid cell engagers using LTZ’s immune-engager platform to target ...

As California highway slides toward sea, the fix will take billions STILLS: Satellite images show Russia's Novorossiysk port ...